HHS Doubles Funding for AI-Backed Childhood Cancer Research
Written by: Diya Sriramagiri
In September 2025, the U.S. Department of Health and Human Services (HHS) announced that funding for the National Cancer Institute’s Childhood Cancer Data Initiative (CCDI) would double from $50 million to $100 million. The additional funding is intended to expand the use of artificial intelligence to improve childhood cancer diagnosis, treatment, prevention, and clinical research. Established in 2019, the CCDI works to collect, standardize, and share cancer data from children, adolescents, and young adults. Childhood cancers are relatively rare, so researchers at a single hospital may have access to only a limited number of patients with a particular diagnosis. Combining information from hospitals, research institutions, clinical trials, and cancer registries can provide researchers with larger and more diverse datasets.
The CCDI Data Ecosystem connects these separate sources through a centralized network of data and research tools. Its goal is to help researchers better understand childhood cancer biology while improving diagnosis, treatment, quality of life, and long-term survivorship. The initiative also seeks to gather data from young people regardless of where they receive care. Under the expanded initiative, HHS plans to use AI to analyze electronic health records, insurance claims, clinical information, and research data. AI systems can examine large amounts of information more quickly than researchers could manually, potentially helping them: Detect patterns connected to cancer risk or treatment response, Identify possible targets for new therapies, Match patients with appropriate clinical trials, Improve the design of future clinical trials. The executive order also directs federal health agencies to form partnerships with private-sector organizations that can contribute advanced AI technology and expertise. HHS states that parents will remain in control of their children’s health information as the data is used for research. Children with cancer do not all have equal access to specialized hospitals, molecular testing, clinical trials, or pediatric oncology experts. These barriers are especially severe for rural families who may need to travel hundreds of miles to reach a major cancer center. A stronger national data system could allow researchers to learn from patients treated across many different locations, not only those receiving care at the country’s largest research hospitals. Collecting information about patients’ communities and social determinants of health could also help researchers identify disparities in clinical-trial participation, treatment access, and health outcomes.
However, better technology will not automatically eliminate these disparities. AI models are only as representative as the information used to train them. If rural patients, racial and ethnic minorities, or children treated outside major academic hospitals are underrepresented in the data, AI-generated conclusions may not work equally well for every patient. Strong privacy protections, transparent oversight, standardized data collection, and representation from diverse communities will therefore be essential. Doubling CCDI funding represents an important commitment to accelerating childhood cancer research. Artificial intelligence may help researchers extract more value from existing health information and uncover connections that would otherwise remain hidden. Nevertheless, scientific discoveries must be paired with policies ensuring that every child can benefit from them. A treatment identified through AI has limited impact if families cannot travel to the hospital offering it, afford temporary housing, receive reliable molecular testing, or enroll in the relevant clinical trial. As the federal government invests in childhood cancer data and technology, it must also address the geographic, financial, and logistical barriers that determine who can access these advances. The next phase of childhood cancer innovation should not be measured only by the discoveries produced. It should also be measured by whether those discoveries reach children in every community.
